Show simple item record

dc.contributor.authorSuppiah, Sen
dc.contributor.authorNassiri, Fen
dc.contributor.authorBi, WLen
dc.contributor.authorDunn, IFen
dc.contributor.authorHanemann, COen
dc.contributor.authorHorbinski, CMen
dc.contributor.authorHashizume, Ren
dc.contributor.authorJames, CDen
dc.contributor.authorMawrin, Cen
dc.contributor.authorNoushmehr, Hen
dc.contributor.authorPerry, Aen
dc.contributor.authorSahm, Fen
dc.contributor.authorSloan, Aen
dc.contributor.authorVon Deimling, Aen
dc.contributor.authorWen, PYen
dc.contributor.authorAldape, Ken
dc.contributor.authorZadeh, Gen
dc.contributor.authorInternational Consortium on Meningiomasen

Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.

dc.format.extenti4 - i17en
dc.titleMolecular and translational advances in meningiomas.en
dc.typeJournal Article
plymouth.issueSuppl 1en
plymouth.journalNeuro Oncolen
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.rights.embargoperiodNot knownen
rioxxterms.typeJournal Article/Reviewen

Files in this item


This item appears in the following Collection(s)

Show simple item record

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV